foxo4-dri senolytic human trial 2024 2025 Frontiers Cellular senescence and senolytics: the
Cellular senescence and senolytics: the path to the clinic Nature Medicine The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53 serine 15 phosphorylation Communications Biology Senolytic Drugs Market Size and Outlook 2031
Pay in 4 interest-free payments of $5.04 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3



